Sulfasalazine is an oral antirheumatic and antibacterial drug used in the treatment of rheumatoid arthritis, ulcerative colitis and related conditions. It works by blocking the enzymes required for the production of prostaglandins, which reduces inflammation and pain. Sulfasalazine is available in both brand and generic forms for its affordability and effectiveness.
Market key trends:
Advancements in treatment methods and growing adoption of combination therapies have accelerated the growth of sulfasalazine market. Research organizations are developing new drug formulations and delivery mechanisms to enhance the efficacy of sulfasalazine. For instance, enteric-coated formulations help deliver the drug directly to the inflamed areas of colon for better management of inflammatory bowel disease. Combination of sulfasalazine with other biologics is also found to be more effective for rheumatoid arthritis. Growing geriatric population suffering from arthritis and inflammatory disorders will further drive the demand for sulfasalazine in the coming years. However, alternative treatment options and side effects associated with long term usage of sulfasalazine may hamper the market growth to some extent.
Segment Analysis
The global sulfasalazine market is dominated by the rheumatoid arthritis sub segment. Sulfasalazine is primarily used for the treatment of rheumatoid arthritis, which is one of the major autoimmune disorders. As per estimates, around 1% of the worldwide population is affected by rheumatoid arthritis. Hence, the high prevalence of the disease and sulfasalazine being one of the main therapy options for rheumatoid arthritis have been driving the growth of the rheumatoid arthritis sub segment.
Key Takeaways
The Global Sulfasalazine Market Demand is expected to witness high growth during the forecast period of 2024 to 2031. The market was valued at US$ 2.32 Bn in 2024 and is projected to reach over US$ 4 Bn by 2031, registering a CAGR of around 18%.
Regional analysis: North America currently dominates the global sulfasalazine market and is expected to maintain its leading position throughout the forecast period. This can be attributed to the strong presence of major players and growing research and development activities in the region. The market in Asia Pacific is anticipated to grow at the fastest pace during the forecast period owing to the rising disease incidence, increasing healthcare expenditure, and growing awareness regarding early diagnosis and treatment.
Key players operating in the sulfasalazine market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptus Biotech S.L., Aptagen LLC, ABiotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Novartis AG and AstraZeneca are the leading players owing to their robust product portfolio and strong geographical presence.
Explore more information on this topic, Please visit -
https://www.trendingwebwire.com/sulfasalazine-market-size-and-demand-analysis/
Comments
0 comment